Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product
Fierce Pharma
JULY 17, 2023
From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular disease—Argenx’s flagship drug Vyvgar | From its initial nod in generalized myasthenia gravis (gMG) in 2021 to a subcutaneous approval this summer—and now, a stellar showing in a second neuromuscular (..)
236 
Let's personalize your content